Characterization of the novel HLA-DPA1*02:03:05 allele by next generation sequencing.


Journal

HLA
ISSN: 2059-2310
Titre abrégé: HLA
Pays: England
ID NLM: 101675570

Informations de publication

Date de publication:
10 2023
Historique:
revised: 09 06 2023
received: 08 06 2023
accepted: 13 06 2023
medline: 5 9 2023
pubmed: 28 6 2023
entrez: 28 6 2023
Statut: ppublish

Résumé

HLA-DPA1*02:03:05 differs from HLA-DPA*02:03:04 by three nucleotide substitution located in exon 3.

Identifiants

pubmed: 37370240
doi: 10.1111/tan.15137
doi:

Substances chimiques

HLA-DPA1 antigen 0
Nucleotides 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

545-546

Informations de copyright

© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Références

Barker DJ, Maccari G, Georgiou X, et al. IPD-IMGT/HLA Database. Nucleic Acids Res. 2023;51:D1053-D1060.
Marsh SG, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2010. Tissue Antigens. 2010;75:291-455.

Auteurs

Abdelhamid Liacini (A)

Department Pathology and Laboratory, Temple University Hospital, Philadelphia, Pennsylvania, USA.
Medicine/Immunogenetics Laboratory, Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA.

Lindsey Peters (L)

Department Pathology and Laboratory, Temple University Hospital, Philadelphia, Pennsylvania, USA.

Shannon Mancini (S)

Department Pathology and Laboratory, Temple University Hospital, Philadelphia, Pennsylvania, USA.

Christopher Gravante (C)

Department Pathology and Laboratory, Temple University Hospital, Philadelphia, Pennsylvania, USA.

Steven Geier (S)

Department Pathology and Laboratory, Temple University Hospital, Philadelphia, Pennsylvania, USA.
Medicine/Immunogenetics Laboratory, Lewis Katz School of Medicine, Philadelphia, Pennsylvania, USA.

Articles similaires

Genome, Chloroplast Phylogeny Genetic Markers Base Composition High-Throughput Nucleotide Sequencing

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C

Classifications MeSH